Jean-Charles Soria and Raffaele Colombo
Oct 26, 2024, 15:59
Jean-Charles Soria: Key insights into the toxicity, efficacy, stability, distribution, and fate of ADCs
Jean-Charles Soria, Senior Vice President and Oncology Therapeutic Area Head at Amgen, shared a post on LinkedIn:
“ADCs represent one of the most rapidly expanding treatment modalities in oncology, with 11 ADCs FDA-approved and more than 210 currently being tested in clinical trials.
Spanning over 40 years, ADC clinical development remains challenging as evident from the clinical discontinuation of more than 150 ADCs to date.
This review discussed key insights into the toxicity, efficacy, stability, distribution, and fate of ADCs.”
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
Authors: Raffaele Colombo, Paolo Tarantino, Jamie R. Rich, Patricia M. LoRusso, Elisabeth G.E. de Vries.
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Oct 26, 2024, 18:39
Oct 26, 2024, 18:30
Oct 26, 2024, 18:28
Oct 26, 2024, 18:16
Oct 26, 2024, 18:03